DarioHealth Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by DarioHealth Corp. (DRIO) on January 10, 2025, reporting events occurring on January 7, 2025. The filing details a private placement financing transaction involving the issuance of new preferred stock to accredited investors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, or debt metrics. The primary financial data point is the capital raised through the offering:
- Gross Proceeds: Approximately $6,824,000.
- Securities Issued: 4,974 shares of Series D-2 Preferred Stock and 1,850 shares of Series D-3 Preferred Stock.
- Purchase Price: $1,000 per share of Preferred Stock.
- Initial Conversion Price: $0.83 per share of Common Stock.
Material Changes
The material change reported is the entry into a definitive agreement for a private placement. The Company has increased its capital base by approximately $6.8 million through the sale of convertible preferred stock. The closing of the transaction is scheduled to occur on or before January 14, 2025.
Terms, Outlook, and Risks
Security Terms:
- Conversion: Shares are convertible at the holder's option into Common Stock at $0.83 per share, subject to beneficial ownership limitations. Automatic conversion occurs on the 12-month anniversary of issuance.
- Dividends: Holders are entitled to dividends equal to 10% of the shares issuable upon conversion for each full quarter anniversary for four quarters, payable upon conversion.
- Voting Rights: Series D-2 votes with Common Stock on an as-converted basis; Series D-3 has no voting rights.
- Liquidation: Preferred Stock holders are paid pari passu with Parity Securities after Senior Securities.
Risks and Contingencies:
- Conversion of Preferred Stock is subject to stockholder approval.
- Securities are unregistered and cannot be resold in the U.S. absent registration or an exemption.
- Beneficial ownership limitations (including a non-waivable 19.99% blocker) apply to conversions.
Investor Verification Checklist
- Verify the final closing date and receipt of the $6,824,000 gross proceeds.
- Confirm the outcome of the required stockholder approval for the conversion of Preferred Stock.
- Review the full text of the Certificates of Designation (Exhibits 3.1 and 3.2) for specific beneficial ownership limitations and adjustment mechanisms.
- Assess the dilution impact on existing common shareholders based on the $0.83 conversion price and the 10% dividend accruals.